Tonix Pharmaceuticals (NASDAQ:TNXP) announces that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application 12/948,828, “Methods and compositions for treating symptoms associated with posttraumatic stress disorder using cyclobenzaprine,” covering the use of Tonmya, or TNX-102 SL, for the treatment of posttraumatic stress disorder (PTSD).
Patent protection is valid until 2030 in the U.S. from date of issuance, which is expected within two months.
This patent protects the method of using Tonmya’s active ingredient cyclobenzaprine to treat PTSD.
Tonmya is a patented sublingual transmucosal formulation of cyclobenzaprine that is in Phase 3 development.
Shares are up 8% premarket on light volume.
Update: On March 21, the company announced the issuance of the patent.
Subscribe for full text news in your inbox